The BITE study - Bleeding In Thrombocytopenia Explained: A nationwide epidemiological and laboratory case cohort study investigating risk factors for bleeding in hemato-oncology patients

Recruiting

Conditions: Hemato-oncological diseases
malignant diseases of the blood.
10018849

Registration Number: NL-OMON55653

Lead Sponsor: eids Universitair Medisch Centrum

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: Not specified

Target Recruitment: 1000

Inclusion Criteria

- Admission in the hospital
AND
- Age >= 18 years
AND
- Hemato-oncology patient, including MDS and AA, admitted for treatment
(chemotherapy, SCT) who is (expected to become) thrombocytopenic with platelet
counts of < 50 for expected at least 5 days and who will possibly be treated
with one or more prophylactic platelet transfusions. (part A and B)
OR
- Hemato-oncology patient who had previous intensive chemotherapy or stem cell
transplantation and who is admitted to the hematology ward for disease or
treatment related events or complications. (part A only)

Exclusion Criteria

- Myeloproliferative disorders

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>- The presence of clinical factors and results of routinely performed<br /><br>laboratory tests compared between bleeding versus non-bleeding patients.<br /><br>- Presence of markers for coagulation-, platelet- and endothelial or vascular<br /><br>dysfunction compared between bleeding versus non-bleeding patients.</p><br>

Secondary Outcome Measures